Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | DHODH | Q02127 | 8/20 | 0.39 |
| ▸ | KCNK2 | O95069 | 1/20 | 0.38 |
| ▸ | KCNK10 | P57789 | 1/20 | 0.38 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.37 |
| ▸ | CFD | P00746 | 2/20 | 0.37 |
| ▸ | MYC | P01106 | 1/20 | 0.37 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29512881 | 1.00 | RORC (0.42) | RORCKDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL20107592 | 1.00 | RORC (0.42) | RORCKDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL28823359 | 0.87 | RORC (0.44) | RORCDHODHSLC6A9 | |
| SCHEMBL29512911 | 0.87 | RORC (0.44) | RORCDHODHSLC6A9 | |
| SCHEMBL20107621 | 0.87 | RORC (0.44) | RORCDHODHSLC6A9 | |
| SCHEMBL30014395 | 0.86 | NR4A2 (0.45) | RORCALDH1A1HSD17B10DHODH | |
| SCHEMBL20242123 | 0.83 | ALDH1A1 (0.54) | KDM4EALDH1A1HPGDHSD17B10GLA | |
| Ethane SCHEMBL6917971 | 0.81 | ALDH1A1 (0.53) | KDM4EALDH1A1HPGDHSD17B10GLA | |
| SCHEMBL20107872 | 0.81 | ALDH1A1 (0.41) | KDM4EALDH1A1HPGDHSD17B10USP2 | |
| SCHEMBL29816552 | 0.81 | ALDH1A1 (0.41) | KDM4EALDH1A1HPGDHSD17B10USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4100124-A1 | HETEROCYCLIC COMPOUNDS AS DIHYDROOROTATE DEHYDROGENASE INHIBITORS | Janssen Biotech, Inc. (US) | 2022-12-14 | — | — | EP | disclosed |
| CN-114921391-A | 4, 5-Cyclic 1,2, 4-triazolones | 拜耳股份有限公司 | 2022-08-19 | — | — | CN | disclosed |
| CN-110023302-B | 2,4, 5-trisubstituted 1,2, 4-triazolones as DHODH inhibitors | 拜耳股份有限公司 | 2022-07-26 | — | — | CN | disclosed |
| CN-110248937-B | 4, 5-Cyclic 1,2, 4-triazolones | 拜耳股份有限公司 | 2022-03-29 | — | — | CN | disclosed |
| US-11130745-B2 | 2,4,5-trisubstituted 1,2,4-triazolones useful as inhibitors of DHODH | BAYER AKTIENGELLSCHAFT (DE) | 2021-09-28 | — | — | US | disclosed |
| WO-2021156787-A1 | HETEROCYCLIC COMPOUNDS AS DIHYDROOROTATE DEHYDROGENASE INHIBITORS | JANSSEN BIOTECH, INC. (US) | 2021-08-12 | — | — | WO | disclosed |
| US-20210188805-A9 | 2,4,5-TRISUBSTITUTED 1,2,4-TRIAZOLONES USEFUL AS INHIBITORS OF DHODH | BAYER AKTIENGESELLSCHAFT (DE) | 2021-06-24 | — | — | US | disclosed |
| US-10968216-B2 | 4,5-annulated 1,2,4-triazolones | BAYER AKTIENGESELLSCHAFT (DE) | 2021-04-06 | — | — | US | disclosed |
| US-20200377472-A1 | 2,4,5-TRISUBSTITUTED 1,2,4-TRIAZOLONES USEFUL AS INHIBITORS OF DHODH | BAYER AKTIENGESELLSCHAFT (DE) | 2020-12-03 | — | — | US | disclosed |
| US-20200123129-A1 | 2,4,5-TRISUBSTITUTED 1,2,4-TRIAZOLONES USEFUL AS INHIBITORS OF DHODH | BAYER AKTIENGESELLSCHAFT (DE) | 2020-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11130745-B2 | 2,4,5-trisubstituted 1,2,4-triazolones useful as inhibitors of DHODH | DHODH, DPYD, DHPS | RORC 1364/4885KDM4E 1038/4885ALDH1A1 135/4885 |
| US-20200123129-A1 | 2,4,5-TRISUBSTITUTED 1,2,4-TRIAZOLONES USEFUL AS INHIBITORS OF DHODH | DHODH, DPYD, DHPS | RORC 1364/4885KDM4E 1038/4885ALDH1A1 135/4885 |
| US-20210188805-A9 | 2,4,5-TRISUBSTITUTED 1,2,4-TRIAZOLONES USEFUL AS INHIBITORS OF DHODH | DHODH, DPYD, DHPS | RORC 1364/4885KDM4E 1038/4885ALDH1A1 135/4885 |
| US-20200377472-A1 | 2,4,5-TRISUBSTITUTED 1,2,4-TRIAZOLONES USEFUL AS INHIBITORS OF DHODH | DHODH, DPYD, DHPS | RORC 1364/4885KDM4E 1038/4885ALDH1A1 135/4885 |
| US-10968216-B2 | 4,5-annulated 1,2,4-triazolones | CCNA1, CCNT1, CCND2 | RORC 866/4885KDM4E 1759/4885ALDH1A1 274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.